MINI FUTURE LONG - POLE GROU Stock

DE000MD97ZC3

Market Closed - Börse Stuttgart 10:14:37 2024-06-28 EDT
1.94 ^EUR	-1.02%

Current month	-15.28%
1 month	-17.45%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart POLYPEPTIDE GROUP AG

Latest news about POLYPEPTIDE GROUP AG

PolyPeptide : and Donaldson collaborate to develop solvent recovery system for peptide purification	05-13	PU
Donaldson Company, Inc. and PolyPeptide Group AG Partners to Improve Sustainability in Peptide Manufacturing with Solvent Recovery Technology	05-13	CI
Hamlet BioPharma secures large scale Alpha1 peptide production in an agreement with Polypeptide Group	04-18	AQ
PolyPeptide announces results of the annual General Meeting 2024	04-10	EQ

More news

Quotes 5-day view

Date	Price	Change
24-06-28	1.94	-1.02%
24-06-27	1.96	-1.01%
24-06-26	1.98	-5.71%
24-06-25	2.1	-2.78%
24-06-24	2.16	-3.57%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 10:14 am

More quotes

Static data

Product type	Knock-Out with Stop Loss
Buy / Sell	CALL
Underlying	POLYPEPTIDE GROUP AG
Issuer	Morgan Stanley
WKN	MD97ZC
ISIN	DE000MD97ZC3
Date issued	2022-10-10
Strike	10.55 CHF
Maturity	Unlimited
Parity	10 : 1
Emission price	2.07 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.88 €
Lowest since issue	0.44 €

Company Profile

Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.

Sector

More about the company

Ratings for PolyPeptide Group AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: PolyPeptide Group AG

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

29.7 EUR

Average target price

25.12 EUR

Spread / Average Target

-15.42%

Consensus